CALICO LIFE SCIENCES LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [14C] ABBV-CLS-7262

First Posted Date: 2024-05-22

Last Posted Date: 2024-07-19

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 7

Registration Number: NCT06425003

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc., Madison, Wisconsin, United States

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABBV-CLS-7262
Drug: Placebo
Drug: Moxifloxacin 400mg

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-01

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 72

Registration Number: NCT06310876

Locations: 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

Expanded Access to ABBV-CLS-484

Conditions: Advanced Solid Tumor Cancer

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: Calico Life Sciences LLC

Registration Number: NCT06188975

A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABBV-CLS-7262

First Posted Date: 2023-11-24

Last Posted Date: 2024-03-08

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 18

Registration Number: NCT06145607

Locations: 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABBV-CLS-7262

First Posted Date: 2023-03-10

Last Posted Date: 2023-06-26

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 12

Registration Number: NCT05763459

Locations: 🇺🇸
AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Phase 1

Recruiting

Conditions: Vanishing White Matter Disease

Interventions: Drug: Fosigotifator

First Posted Date: 2023-03-07

Last Posted Date: 2025-05-25

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 50

Registration Number: NCT05757141

Locations: 🇺🇸
Massachusetts General Hospital /ID# 270960, Boston, Massachusetts, United States
🇺🇸
University of Utah /ID# 255624, Salt Lake City, Utah, United States
🇳🇱
Amsterdam UMC, locatie VUmc /ID# 270955, Amsterdam, Noord-Holland, Netherlands

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

Phase 1

Active, not recruiting

Conditions: ALS
Amyotrophic Lateral Sclerosis

Interventions: Drug: Fosigotifator
Drug: Placebo

First Posted Date: 2021-07-02

Last Posted Date: 2024-05-28

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 31

Registration Number: NCT04948645

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins ALS Clinical Trials Unit, Baltimore, Maryland, United States
🇺🇸
Healey & AMG Center for ALS Research, Boston, Massachusetts, United States

and more 10 locations

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor Cancer

Interventions: Drug: ABBV-CLS-484
Drug: Programmed Cell Death-1 (PD-1) Inhibitor
Drug: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)

First Posted Date: 2021-03-02

Last Posted Date: 2025-06-03

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 248

Registration Number: NCT04777994

Locations: 🇺🇸
University of Arizona Cancer Center - Tucson /ID# 262698, Tucson, Arizona, United States
🇺🇸
Yale University School of Medicine /ID# 225707, New Haven, Connecticut, United States
🇺🇸
Johns Hopkins Hospital /ID# 254056, Baltimore, Maryland, United States

and more 27 locations

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-CLS-579
Drug: PD-1 inhibitor
Drug: VEGFR TKI

First Posted Date: 2020-06-04

Last Posted Date: 2023-12-07

Lead Sponsor: Calico Life Sciences LLC

Target Recruit Count: 263

Registration Number: NCT04417465

Locations: 🇺🇸
Highlands Oncology Group Springdale, Springdale, Arkansas, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States

and more 14 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy